Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 7/20 | 0.40 |
| ▸ | HTR2B | P41595 | 6/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.32 |
| ▸ | CD44 | P16070 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30590165 | 1.00 | ASIC3 (0.42) | ASIC3HTR2CHTR2BCYP3A4POLB | |
| Hydrochloric Acid SCHEMBL30331765 | 0.98 | ASIC3 (0.41) | ASIC3HTR2CHTR2BCYP3A4POLB | |
| Hydrochloric Acid SCHEMBL1119771 | 0.98 | ASIC3 (0.41) | ASIC3HTR2CHTR2BCYP3A4POLB | |
| Hydrochloric Acid SCHEMBL1119948 | 0.98 | ASIC3 (0.41) | ASIC3HTR2CHTR2BCYP3A4POLB | |
| Hydrochloric Acid SCHEMBL1119945 | 0.98 | ASIC3 (0.41) | ASIC3HTR2CHTR2BCYP3A4POLB | |
| SCHEMBL25156600 | 0.87 | CYP3A4 (0.35) | ASIC3HTR2CHTR2BCYP3A4POLB | |
| SCHEMBL30624154 | 0.87 | ASIC3 (0.42) | ASIC3HTR2CHTR2BALDH1A1HTR2A | |
| SCHEMBL621045 | 0.84 | ALDH1A1 (0.34) | ASIC3HTR2CHTR2BPOLBSMN1; SMN2 | |
| SCHEMBL13761127 | 0.83 | CYP3A4 (0.37) | ASIC3HTR2CHTR2BCYP3A4POLB | |
| Hydrochloric Acid SCHEMBL622126 | 0.83 | ALDH1A1 (0.33) | ASIC3HTR2CHTR2BPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135475-A1 | Process for the preparation of ccr-2 antagonists | MERCK SHARP & DOHME CORP. | 2007-06-14 | — | — | US | claimed |
| JP-2007509944-A | — | — | 2007-04-19 | — | — | JP | claimed |
| EP-1682500-A1 | PROCESS FOR THE PREPARATION OF CCR-2 ANTAGONIST | Merck & Co., Inc. (US) | 2006-07-26 | — | — | EP | claimed |
| WO-2005044795-A1 | PROCESS FOR THE PREPARATION OF CCR-2 ANTAGONIST | MERCK & CO., INC. (US) | 2005-05-19 | — | — | WO | claimed |
| EP-4482527-B1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20250154288-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-05-15 | — | — | US | disclosed |
| WO-2024220641-A1 | 1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 USEFUL FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2024-10-24 | — | — | WO | disclosed |
| WO-2023161874-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161874-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023064585-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064587-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064584-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2005044795-A8 | PROCESS FOR THE PREPARATION OF CCR-2 ANTAGONIST | MERCK & CO INC (US) | 2006-06-22 | — | — | WO | disclosed |
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-04-06 | — | — | US | disclosed |
| US-20050267146-A1 | 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2005-12-01 | — | — | US | disclosed |
| WO-2005044264-A1 | CCR-2 ANTAGONIST SALT | MERCK & CO., INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005044264-A1 | CCR-2 ANTAGONIST SALT | MERCK & CO., INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005044795-A1 | PROCESS FOR THE PREPARATION OF CCR-2 ANTAGONIST | MERCK & CO., INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005044795-A1 | PROCESS FOR THE PREPARATION OF CCR-2 ANTAGONIST | MERCK & CO., INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2004069162-A2 | 3-AMINO-4-PHENYLBUTANOIC ACID DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | ASIC3 580/4885HTR2C 2255/4885HTR2B 1666/4885 |
| US-20250154288-A1 | CYTOTOXICITY TARGETING CHIMERAS FOR C-C CHEMOKINE RECEPTOR 2-EXPRESSING CELLS | CCR2, CCRL2, CCR5 | ASIC3 4413/4885HTR2C 2620/4885HTR2B 3508/4885 |
| US-20070135475-A1 | Process for the preparation of ccr-2 antagonists | CCR1, CCR2, CCR4 | ASIC3 93/4885HTR2C 301/4885HTR2B 686/4885 |
| US-20050267146-A1 | 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | CCR5, CXCR3, CCR2 | ASIC3 1158/4885HTR2C 743/4885HTR2B 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.